
AZ expands China operations, agrees obesity deal with CSPC
AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the companies will initially progress four programmes, which utilise CSPC's AI-driven peptide drug discovery platform and its LiquidGel once-monthly dosing platform… Read More















